A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives

Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
12/2001
12/05/2001	CN1325301A Controlled delivery of active agents
12/05/2001	CN1325300A Pharmaceutical formulation comprising omeprazole
12/05/2001	CN1325299A Orally administered controlled drug delivery system providing temporal and spatial control
12/05/2001	CN1325298A Method for producing solid dosing forms
12/05/2001	CN1325271A Compositions of restricted cells capable of rapid growth which produce proliferation suppressive materials, and uses thereof
12/05/2001	CN1324613A Use of taxiol stabilized by albumin in preparing emdicine for treating body tumor and medicine obtained therefrom
12/05/2001	CN1324610A Use of sunblock composition using aminohydrox-diphenyl methanone as necessary components in light-stabilizing UV filtering agent, in cosmetics and medicines
12/05/2001	CN1324607A Anti-fungus agent for local treatment of fungus infection of finger and its peripheral tissue and controllable releasable system of keratin-dissolving agnt
12/05/2001	CN1075736C Virus inactivation method for high-density protein preparation
12/04/2001	US6326475 Dry acid-chitosan complexes
12/04/2001	US6326467 Peptide hormones, lh-rh
12/04/2001	US6326406 Heating aqueous solution containing lecithin and bile acid salt
12/04/2001	US6326401 Formulation for the oromucosal, in particular pernasal, route
12/04/2001	US6326384 Dry blend pharmaceutical unit dosage form
12/04/2001	US6326360 Bubbling enteric coated preparations
12/04/2001	US6326357 Bacterial cell complex composition and method of use
12/04/2001	US6326356 Antitumor agents
12/04/2001	US6326353 123therapy for septic shock; administering polymyxin by injection
12/04/2001	US6326195 Recombinant retroviral vector
12/04/2001	US6326028 Alginate and gellan gum as tablet coating
12/04/2001	US6326027 Solid, oral dosage form, comprising tramadol or its salt in matrix providing at least twelve hour effectiveness
12/04/2001	US6326023 Synergistic anti-malarial formulation
12/04/2001	US6326009 Parenterally administering carbohydrate antigenic primer (determinant) bearing antigen; conjugated to animmunogenic carrier
12/04/2001	US6325993 Oral adhesive sheet and oral adhesive preparation
12/04/2001	US6325991 Methods and compositions for treating periodontal disease with an inhibitor of secretory phospholipase A2
12/04/2001	US6325990 Film forming composition for spraying on the skin
12/04/2001	CA2197941C A pharmaceutical tablet characterized by a showing high volume increase when coming into contact with biological fluids
12/04/2001	CA2139948C Targeting somatic gene therapy to joints
12/04/2001	CA2085884C Pressurized hydrofluorocarbon aerosol compositions
11/2001
11/29/2001	WO2001090251A1 Antimicrobial composition
11/29/2001	WO2001090245A1 Solutizing agents
11/29/2001	WO2001090198A1 Multicomponent conjugates which bind to target molecules and stimulate cell lysis
11/29/2001	WO2001090159A2 Compositions and methods for delivery of a molecule into a cell
11/29/2001	WO2001090153A2 Reagents for cell selection and methods of use
11/29/2001	WO2001090144A2 Vip-related peptides for the treatment of sexual disorders in women
11/29/2001	WO2001090129A2 Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with mono and disaccharide-base compounds
11/29/2001	WO2001090057A1 Sulfonamide derivatives
11/29/2001	WO2001089678A2 Emulsifiers
11/29/2001	WO2001089616A1 Aerosol container for formulations of salmeterol xinafoate
11/29/2001	WO2001089593A1 Transfection system
11/29/2001	WO2001089588A1 Sterilization of silicone preparations
11/29/2001	WO2001089579A2 Composition for delivery of compounds to cells
11/29/2001	WO2001089578A1 Acetazolamide-based ophthalmic solution
11/29/2001	WO2001089577A2 Conjugates of aminodrugs comprising an oxime bond
11/29/2001	WO2001089576A2 Preparation hypericin bonded with poly-n-vinylamides
11/29/2001	WO2001089574A1 Solid dispersion system of pranlukast with improved dissolution, and the preparing method thereof
11/29/2001	WO2001089573A1 Method of stabilizing preparation
11/29/2001	WO2001089572A1 Systems and methods for topical treatment with nitric oxide
11/29/2001	WO2001089571A2 Method of increased bioavailability of nutrients and pharmaceutical preparations with tetrahydropiperine and its analogues and derivatives
11/29/2001	WO2001089561A1 Aids vaccines
11/29/2001	WO2001089559A2 Porcine reproductive and respiratory syndrome virus (prrsv) recombinant avipoxvirus vaccine
11/29/2001	WO2001089558A2 Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states
11/29/2001	WO2001089544A1 Antimigraine combination comprising sapindus and emblica extracts
11/29/2001	WO2001089542A2 Composition for improving the cell protection comprising a lipophilic antioxidant and a hydrophilic antioxidant
11/29/2001	WO2001089523A1 New pharmaceutical composition and the process for its preparation
11/29/2001	WO2001089522A1 Compositions and methods for administration of pharmacologically active compounds
11/29/2001	WO2001089521A1 Medicinal compositions containing thiophene derivatives
11/29/2001	WO2001089520A2 Dehydroascorbic acid formulations and uses thereof
11/29/2001	WO2001089514A2 Pharmaceutical composition comprising a free-radical scavenging sedative agent and a metal ion chelating agent
11/29/2001	WO2001089507A1 NOVEL FORMULATIONS OF α-2,4-DISULFOPHENYL-N-TERT-BUTYLNITRONE
11/29/2001	WO2001089494A2 Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases
11/29/2001	WO2001089492A1 Novel composition
11/29/2001	WO2001089491A1 Novel process
11/29/2001	WO2001089487A1 Transdermal therapeutical system with a reduced tendency of the active substance to crystallize
11/29/2001	WO2001089486A1 Nonoral preparation having three-layer structure
11/29/2001	WO2001089485A1 Rapidly disintegrating tablet and process for the manufacture thereof
11/29/2001	WO2001089483A1 Tablets and methods for modified release of hydrophilic and other active agents
11/29/2001	WO2001089482A2 Method for preparing microparticles having a selected polymer molecular weight
11/29/2001	WO2001089481A1 Prolonged release microspheres for injection delivery and preparation method
11/29/2001	WO2001089480A1 Stable pharmaceutical solution formulations for pressurised metered dose inhalers
11/29/2001	WO2001089479A2 Sustained release pharmaceutical compositions for parenteral administration of hydrophilic compounds
11/29/2001	WO2001089478A1 Carbohydrate medical solution and sulphite stabilisator in a multiple compartment container and use thereof
11/29/2001	WO2001089476A1 Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements
11/29/2001	WO2001089474A2 O/w emulsion
11/29/2001	WO2001089473A1 Pharmaceutical compositions comprising desglymidodrine as an active drug substance
11/29/2001	WO2001089469A1 Topical composition containing at least one aryl oxime, and method for the preparation thereof
11/29/2001	WO2001089449A2 Phospholipase d effectors for therapy and screening
11/29/2001	WO2001058935A3 FACTOR VII OR VIIa-LIKE MOLECULES
11/29/2001	WO2001037816A3 Coating of tablet cores
11/29/2001	WO2001028544A3 Dialysis solution including polyglycol osmotic agent
11/29/2001	WO2001021211A3 Process for lessening polymorphic conversion of a drug
11/29/2001	WO2001005433A3 Delivery and retention of activity agents to lymph nodes
11/29/2001	WO2000053229A3 Protein conjugates on the basis of lumazine synthase, methods for producing them and the use thereof
11/29/2001	WO2000045792A8 Hydrogel particle formulations
11/29/2001	WO2000041548A3 Methods for glucagon suppression
11/29/2001	US20010047161 Osmotically-driven fluid dispenser and composition
11/29/2001	US20010047081 Adenoviral capsid containing chimeric protein IX
11/29/2001	US20010047074 Self-assembling colloidal carriers for protein delivery
11/29/2001	US20010047034 Inhibiting oxidative degradation of pharmaceutical formulations
11/29/2001	US20010047009 'anti-plaque emulsions and products containing same'
11/29/2001	US20010047000 E.g., ranolazine
11/29/2001	US20010046988 Especially treating fibromyalgia, chronic fatigue syndrome, psychogenic pain and chromic pain
11/29/2001	US20010046970 Inhibition of selectin binding
11/29/2001	US20010046964 Drug core with two coated membrane barriers, one of which is composed of an enteric polymer and the other with a combination of an enteric polymer and a water soluble polymer
11/29/2001	US20010046961 Method for the treatment of solid tumors by albumin microparticles incorporating paclitaxel
11/29/2001	US20010046957 Administering interferon-alpha or a pegylated derivative and a salt or prodrug of mycophenolic acid
11/29/2001	US20010046954 Bioavailability enhancing compound which may be non-reducing carbohydrate; amino acid or polymer; hydroxamate; or oxo-acid salt, especially s basic sodium phosphate; suspended in a hydrophobic carrier; increasing milk production
11/29/2001	US20010046705 Complex of nucleic acid and biodegradable cationic polyhydroxylated molecule (e.g., maltodextrin grafted with glycidyltrimethylammonium chloride); protects nucleic acid during transfection in to a cell
11/29/2001	US20010046519 Compositions for nasal administration
11/29/2001	US20010046516 Combining a sustained release excipient comprises a gelling agent, an ionizable gel strength enhancer and inert diluent with a medicament in amorphous form and a wetting agent and then drying and millilng the combined mixture

1 ... 1280 1281 1282 1283 1284 1285 1286 1287 1288 1289 1290 1291 1292 1293 1294 1295 1296 1297 1298 1299 1300 ... 1712